An endpoint for worsening asthma: Development of a sensitive measure and its properties

Drug Information Journal

Volumn 38, Issue 1, 2004, Pages 5-13

  Zhang, Ji ^a,b   Song, Cindy ^a   Reiss, Theodore F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Biostatistics   (United States)

Author keywords

Asthma worsening; Clinical trial; Validated endpoint; Worsening asthma

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADULT; AGED; AROUSAL; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 2942707591     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150403800103     Document Type: Article

References (24)

1. 1, PEF, and daytime symptom score. Am J Respir Crit Care Med. 1997;155:A889.
2. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled β-agonists in asthma: effects on exacerbations and lung function. Thorax. 1993;48:134-138.
3. Pauwels RA, Lofdahl C, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
4. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488.
5. National Institutes of Health. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health; 1995. Publication 95-3659.
6. Zhang J, Reiss TF. Defining and analyzing asthma exacerbations. Control Clin Trials. 1995;16:52S.
7. Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol. 1998;102:50-56.
8. Santanello NC, Barber BL, Friedman BS, Reiss TF, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J. 1997;10:646-651.
9. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J. 1998;11:1232-1239.
10. Zhang J, Yu C and Reiss T. Predicting future response using patient baseline characteristics and early response to montelukast, a potent CYS LT-1 antagonist. Am J Respir Crit Care Med. 1999;159:A640-A640.
11. Searle SR, Casella G, McCulloch CE. Variance Components. New York, NY: John Wiley & Sons, Inc.; 1992.
12. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83.
13. Rozas CJ, Goldman AL. Daily spirometric variability: normal subjects and subjects with chronic bronchitis with and without airflow obstruction. Arch Intern Med. 1982;142:1287-1291.
14. Pennock RE, Rogers RM, McCaffree DR. Changes in measured spirometric indices: what is significant? Chest. 1981;80:97-99.
15. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
16. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet. 1999;353:364-369.
17. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol. 1992;45:1341-1345.
18. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990;85:1098-1112.
19. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Int Med. 1998;158:1213-1220.
20. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Int Med. 1999;130:487-495.
21. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
22. Follmann D, Wittes J, Cutler JA. The use of subjective rankings in clinical trials with an application to cardiovascular disease. Stat Med. 1992;11:427-437.
23. Williford WO, Krol WF, Spechler SJ. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. Control Clin Trials. 1994;15:335-348.
24. Gibson PG, Wlodarczyk J, Hensley MJ, Murree-Allen K, Olson LG, Saltos N. Using quality-control analysis of peak expiratory flow recordings to guide therapy for asthma. Ann Int Med. 1995;123:488-492.